Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Galactomannan Derivative

Other · Acts on galectins · developed by Galectin Therapeutics

Phase 2 Most advanced trial (none active)

GALT Developer

1 Registered trials

What is Galactomannan Derivative?

GM-CT-01 is a galactomannan derivative, a carbohydrate polymer of mannose and galactose. It binds galectins on the surface of cells and may promote the transport of 5-fluorouracil into tumor cells. It is studied with 5-FU in colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: GM-CT-01
Drug type: Other
Targets: galectins
Mechanism: Acts on galectins
Pathways: 5-FU transport into tumor cells
Therapy area: Oncology
Developer: Galectin Therapeutics Inc. (GALT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00388700	Phase 2	Colorectal Cancer	Withdrawn	GALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Cancer

More from Galectin Therapeutics

Belapectin Phase 2/3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GALT page.

Follow GALT, the company behind Galactomannan Derivative

See GALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GALT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z